MyOrbitHealth vs. Fuse Health: Beyond Peptides (2026)

Here is the short answer. Fuse Health positions itself as the "Shopify for peptides": a specialized platform for launching a peptide telehealth brand, sold on tiered subscription pricing as of mid-2026. If a peptide brand is the only thing you will ever build, that specialization is a legitimate argument in Fuse's favor. MyOrbitHealth is multi-vertical, API-first white-label telehealth infrastructure that supports peptides plus ten other verticals on one stack: GLP-1 weight loss, HRT, TRT and men's health, women's health, sexual wellness, hair and skin, mental health, primary care, sleep, and longevity. Behind it sit named products (OrbitOS, the multi-tenant clinical console; Orbit Intake, AI-driven adaptive medical intake with severity scoring; OrbitRx, EPCS-ready e-prescribing routed via Surescripts to a LegitScript-certified pharmacy network), a network of 1,240+ board-certified providers across 38+ specialties in all 50 states with an average response under six minutes during business hours, and a REST API with webhooks and a React SDK.

The decision comes down to one question: is "peptide brand" your business, or your first product? Most successful health brands expand, and switching infrastructure partners mid-growth is expensive. This post compares the two honestly, dimension by dimension, so you can answer that question for yourself.

Key takeaways

• Fuse Health is a peptide-focused telehealth platform ("Shopify for peptides") with tiered subscription pricing as of mid-2026, and its specialization is a real advantage for brands that will only ever sell peptides.
• MyOrbitHealth supports peptides plus ten other verticals (including GLP-1 weight loss, TRT, and longevity) on a single stack, so a brand can expand without changing infrastructure partners.
• Switching telehealth infrastructure partners mid-growth typically means patient migration, standing up a new provider network relationship, and re-working compliance, which is why the expansion question belongs in the initial platform decision.
• MyOrbitHealth's stack includes OrbitOS, Orbit Intake, OrbitRx, a 1,240+ provider network across 38+ specialties in all 50 states, and a REST API with webhooks and a React SDK; as of mid-2026, Fuse does not lead with a developer product, and no direct competitor pairs an API with a React SDK.
• As of mid-2026, Fuse publishes subscription tiers while MyOrbitHealth pricing is discussed on a demo call, so budget comparisons require a conversation with each.

What is Fuse Health and who is it actually for?

Fuse Health's positioning, as of mid-2026, is "Shopify for peptides." Shopify won by making one job (launching an online store) radically easier, and Fuse applies the same logic to one telehealth category: brands built around peptide protocols. The product is shaped for that niche, and the company sells it through tiered subscription pricing, which makes it easier to budget against on day one than demo-gated platforms.

Give credit where it is due. A platform that lives entirely inside the peptide category can shape its intake flows, its content, and its onboarding around that single vertical. If you are a fitness creator or a wellness operator whose entire thesis is peptides, and you are confident that thesis will not change, Fuse's focus is a genuine argument, not a weakness we are pretending is a strength. We will not spin that.

The question a founder has to sit with is whether "peptides only, forever" describes their actual business plan. In our experience talking to operators, it rarely does. Peptides are frequently the wedge, not the whole company. The customer who buys a recovery peptide protocol is often the same customer who asks about GLP-1s for weight loss, TRT for energy, or a broader longevity program six months later. If you want the mechanics of the wedge itself, our guide to starting an online peptide business covers sourcing, compliance, and launch step by step.

How do MyOrbitHealth and Fuse Health compare at a glance?

Where we describe Fuse, we are working from its public positioning as of mid-2026; confirm specifics on your own sales call, because offerings change.

Why does vertical coverage matter if you only sell peptides today?

Because your roadmap is longer than your launch plan.

Look at how consumer health brands actually grow. The pattern repeats: a brand launches with one hero category, builds an audience and a patient base, then expands into adjacent categories where the margin and the retention live. Weight loss brands add hormone optimization. Men's health brands add hair loss. Peptide brands add GLP-1s, because the customer overlap is enormous; the person optimizing recovery and body composition with peptides is squarely in the market for medically supervised weight management. If GLP-1s are on your roadmap at all, read our guide to launching a GLP-1 weight loss brand before you sign anything, because your infrastructure choice today decides how painful that expansion is.

On a single-vertical platform, expansion has two options, and both are expensive. Option one: bolt a second infrastructure partner alongside the first, which means two provider relationships, two compliance surfaces, two patient databases, and a patient experience stitched together at the seams. Option two: migrate everything to a multi-vertical partner, which means moving patient records under HIPAA constraints, re-establishing provider relationships, re-doing pharmacy routing, and re-validating your compliance posture, all while the existing business keeps running. Neither is a weekend project, and the true cost is never the new vendor's invoice; it is the months of attention the migration eats.

On MyOrbitHealth, expansion is a configuration decision, not a migration. The same OrbitOS console holds the patient record, the same 1,240+ provider network spans 38+ specialties, and OrbitRx already routes to a LegitScript-certified pharmacy network covering compounding and retail. Launch on our platform, add another line when the data says your audience wants it, and your patients never feel the plumbing change.

How do the platforms compare on technology and API depth?

Fuse's "Shopify for peptides" framing implies a productized storefront-and-clinic experience for its niche, and for its target buyer that packaging is the point: less to configure, less to decide. It does not lead with a developer product; as of mid-2026, among direct competitors only Telegra also offers a public API, and none pairs one with a React SDK. Confirm integration options on a demo if you have an existing app.

MyOrbitHealth ships both integration paths. Non-technical founders run on the fully white-labeled hosted clinic: Orbit Intake handles AI-driven adaptive medical intake with severity scoring and red-flag escalation under your brand, OrbitOS gives your team the clinical console with role-based access and a full HIPAA audit trail, and OrbitRx handles prescribing and fulfillment. Product and engineering teams take the second path: a REST API with webhooks and a React SDK, so telehealth becomes a feature inside software you already run rather than a separate destination. A fitness platform adding peptide protocols for its members, for example, can keep its own front end and let the API handle intake, encounters, and prescriptions behind it.

If you are still mapping what a white-label platform should include at each layer, our white-label telehealth platform guide is the place to start; it will sharpen your demo questions for any vendor, including us.

What about provider networks, pharmacy, and compliance?

Peptides are a clinically and regulatorily sensitive category, so this section deserves your closest reading regardless of which platform you pick.

On providers: MyOrbitHealth operates a network of 1,240+ board-certified providers across 38+ specialties covering all 50 states, with an average response under six minutes during business hours. The specialty breadth is what makes multi-vertical expansion real rather than theoretical; the network that reviews your peptide intakes today already includes the specialties your GLP-1 or TRT line will need tomorrow. Fuse's clinical coverage is built around its peptide programs; ask directly about state coverage, consult turnaround, and protocol flexibility on your demo, as you should with every vendor.

On pharmacy: peptide fulfillment runs through compounding pharmacies, and pharmacy quality is where peptide brands live or die. OrbitRx routes EPCS-ready e-prescriptions via Surescripts to a LegitScript-certified pharmacy network spanning compounding and retail. The LegitScript piece matters beyond compliance box-checking: major ad platforms generally require certification before allowing prescription-adjacent advertising, so your pharmacy partner's certification posture affects your marketing ceiling. Ask Fuse how its fulfillment network handles certification; hedge every vendor's answer against what they will put in writing.

On the legal layer: MyOrbitHealth is a technology company and does not practice medicine. The structure that lets a non-clinician founder own a telehealth brand is the MSO model, with licensed providers delivering care through professional entities while you own the brand and customer relationship. The stack is HIPAA compliant with a BAA included in every contract, runs SOC 2 controls on HITRUST-aligned architecture with US-region encrypted data residency, and EPCS prescribing is backed by two-factor identity proofing.

This is general information, not legal advice; consult a healthcare attorney for your specific structure.

How do Fuse Health and MyOrbitHealth compare on pricing?

Two different models, and the difference is worth understanding on its own terms.

Fuse publishes tiered subscription pricing as of mid-2026. Published tiers are genuinely buyer-friendly: you can budget before you ever talk to sales, and you can see how costs step up as you grow. We will not quote their numbers here because tiers change; check their site for current figures.

MyOrbitHealth pricing is discussed on a demo call, as of mid-2026. We know demo-gated pricing is a real drawback for buyers who want to self-serve a budget, and we will not pretend otherwise. The practical reason is that multi-vertical programs vary widely: a single-vertical peptide launch, a med spa adding three lines, and an API integration into an existing product carry different economics.

Whichever vendor you talk to, compare total cost of operation rather than the headline fee: per-consult economics, pharmacy and medication markups, setup fees, minimum commitments, and what an added vertical costs. A cheap platform that requires a second platform (or a migration) at expansion time is not cheap. For a wider look at how the category prices and who leads where, our roundup of the best white-label telehealth platforms puts Fuse, MyOrbitHealth, and the rest side by side with honest pros and cons.

Who should pick which platform?

Pick Fuse Health if: peptides are your entire thesis, you are confident that will not change, you value a platform shaped around one category, and published subscription tiers matter to how you budget. That is a coherent buyer profile, and for it, Fuse's focus is a real advantage.

Pick MyOrbitHealth if: peptides are your wedge and not your ceiling. You want one partner covering the 1,240+ provider network across 38+ specialties, OrbitRx routing into a LegitScript-certified pharmacy network, the MSO compliance structure, and branded technology as either a hosted clinic or a REST API with a React SDK, with the option to add GLP-1s, TRT, longevity, or any of the other verticals on the same stack when your audience asks for them.

The honest framing: Fuse optimizes for where your brand starts. MyOrbitHealth optimizes for where it is going. Decide which risk you would rather carry.

Frequently asked questions

Is Fuse Health only for peptide brands?

That is its stated focus as of mid-2026: Fuse positions itself as the "Shopify for peptides," a platform specialized for launching peptide telehealth brands. Specialization is the core of its pitch rather than a limitation it hides. Confirm on a demo whether it supports categories beyond peptides, because offerings change.

What is the best Fuse Health alternative for a peptide brand that plans to expand?

A multi-vertical infrastructure partner, so expansion does not require a migration. MyOrbitHealth supports peptides alongside GLP-1 weight loss, TRT, HRT, longevity, and six other verticals on one stack, with 1,240+ board-certified providers across 38+ specialties in all 50 states. That lets a brand launch with peptides and add categories without changing partners.

Does Fuse Health publish pricing?

Fuse lists tiered subscription pricing as of mid-2026, which makes early budgeting easier than with demo-gated competitors. MyOrbitHealth pricing is discussed on a demo call. Compare total cost of operation across both, including per-consult fees, medication markups, and what adding a vertical costs.

How hard is it to switch telehealth infrastructure partners later?

Harder than most founders budget for. A switch typically involves migrating patient records under HIPAA constraints, establishing a new provider network relationship, re-working pharmacy routing, and re-validating your compliance posture while the existing business keeps running. That is why the expansion question belongs in your initial platform decision, not your year-two planning.

Can I run a peptide telehealth brand without a medical license on either platform?

Yes, that is the core promise of white-label telehealth infrastructure. Licensed providers deliver the medical care through the platform's affiliated professional entities, while you own the brand, marketing, and customer relationship under a compliant structure such as the MSO model. Verify how each vendor structures this, because the details carry legal weight.

Does MyOrbitHealth have an API for peptide telehealth?

Yes. MyOrbitHealth offers a REST API with webhooks and a React SDK, so teams can embed intake, encounters, and e-prescribing into an existing product instead of adopting a separate hosted platform. As of mid-2026, Fuse does not lead with a developer product, and no direct competitor pairs an API with a React SDK.

Ready to compare for yourself?

Take the same list of questions to both vendors: state coverage, consult turnaround, pharmacy certification, what an added vertical costs, and what a migration would look like if you outgrow the platform. See who answers plainly. Start with us. Book a demo with MyOrbitHealth at myorbithealth.com and bring your peptide roadmap, plus whatever you think comes after it.